Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Exchange Rate Effect (2016 - 2025)

Historic Exchange Rate Effect for Ptc Therapeutics (PTCT) over the last 11 years, with Q3 2025 value amounting to -$6.1 million.

  • Ptc Therapeutics' Exchange Rate Effect fell 17099.04% to -$6.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.3 million, marking a year-over-year decrease of 352.94%. This contributed to the annual value of -$7.3 million for FY2024, which is 33532.43% down from last year.
  • According to the latest figures from Q3 2025, Ptc Therapeutics' Exchange Rate Effect is -$6.1 million, which was down 17099.04% from $13.6 million recorded in Q2 2025.
  • Over the past 5 years, Ptc Therapeutics' Exchange Rate Effect peaked at $13.6 million during Q2 2025, and registered a low of -$12.1 million during Q3 2022.
  • Moreover, its 5-year median value for Exchange Rate Effect was -$1.7 million (2021), whereas its average is -$99473.7.
  • In the last 5 years, Ptc Therapeutics' Exchange Rate Effect tumbled by 5751428.57% in 2021 and then surged by 50885.48% in 2023.
  • Ptc Therapeutics' Exchange Rate Effect (Quarter) stood at -$3.9 million in 2021, then soared by 254.84% to $6.0 million in 2022, then plummeted by 48.59% to $3.1 million in 2023, then plummeted by 379.58% to -$8.7 million in 2024, then grew by 29.92% to -$6.1 million in 2025.
  • Its last three reported values are -$6.1 million in Q3 2025, $13.6 million for Q2 2025, and $5.4 million during Q1 2025.